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Abstract
Introduction: The purpose was to test the hypothesis that muscle
perfusion, oxygenation, and microvascular reactivity would improve
in patients with severe sepsis or septic shock during treatment
with recombinant activated protein C (rh-aPC) (n = 11) and to
explore whether these parameters are related to macrohemo-
dynamic indices, metabolic status or Sequential Organ Failure
Assessment (SOFA) score. Patients with contraindications to rh-
aPC were used as a control group (n = 5).
Materials and methods: Patients were sedated, intubated,
mechanically ventilated, and hemodynamically monitored with the
PiCCO system. Tissue oxygen saturation (StO2) was measured
using near-infrared spectroscopy (NIRS) during the vascular
occlusion test (VOT). Baseline StO2 (StO2 baseline), rate of
decrease in StO2 during VOT (StO2 downslope), and rate of increase
in StO2 during the reperfusion phase (StO2 upslope) were
determined. Data were collected before (T0), during (24 hours
(T1a), 48 hours (T1b), 72 hours (T1c) and 96 hours (T1d)) and 6
hours after stopping rh-aPC treatment (T2) and at the same times
in the controls. At every assessment, hemodynamic and metabolic
parameters were registered and the SOFA score calculated.
Results:  The mean ± standard deviation Acute Physiology and
Chronic Health Evaluation II score was 26.3 ± 6.6 and 28.6 ± 5.3
in rh-aPC and control groups, respectively. There were no
significant differences in macrohemodynamic parameters between
the groups at all the time points. In the rh-aPC group, base excess
was corrected (P <0.01) from T1a until T2, and blood lactate was
significantly decreased at T1d and T2 (2.8 ± 1.3 vs. 1.9 ± 0.7
mmol/l;  P  <0.05). In the control group, base excess was
significantly corrected at T1a, T1b, T1c, and T2 (P <0.05). The
SOFA score was significantly lower in the rh-aPC group compared
with the controls at T2 (7.9 ± 2.2 vs. 12.2 ± 3.2; P <0.05). There
were no differences between groups in StO2 baseline. StO2 downslope
in the rh-aPC group decreased significantly at all the time points,
and at T1b and T2 (–16.5 ± 11.8 vs. –8.1 ± 2.4%/minute) was
significantly steeper than in the control group. StO2 upslope
increased and was higher than in the control group at T1c, T1d
and T2 (101.1 ± 62.1 vs. 54.5 ± 23.8%/minute) (P <0.05).
Conclusions:  Treatment with rh-aPC may improve muscle
oxygenation (StO2 baseline) and reperfusion (StO2 upslope) and,
furthermore, rh-aPC treatment may increase tissue metabolism
(StO2 downslope). NIRS is a simple, real-time, non-invasive technique
that could be used to monitor the effects of rh-aPC therapy at
microcirculatory level in septic patients.
Introduction
During sepsis, the microcirculatory and mitochondrial dys-
function plays a key role in the development of severe sepsis,
septic shock, and multiple organ failure [1]. This condition is
characterized by microcirculatory perfusion heterogeneity,
arteriovenous shunting, and impaired autoregulation mainly
due to disturbed coagulation, inflammation, and leukocyte–
endothelium interaction [1-3]. It is now well established in
septic patients that restoring basic macrohemodynamic
parameters, such as blood pressure, in itself does not lead to
improved patient outcome, and that normalization of
microcirculatory and mitochondrial function may be necessary
as an endpoint [2,4].
To this end, recombinant activated protein C (rh-aPC) has
been used to restore the coagulative cascade, the inflam-
matory response, leukocyte adhesion and migration, and
endothelial function. In previous studies, rh-aPC has been
shown to decrease end-organ dysfunction and mortality if
administered in the early stages of sepsis [5-7].
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Near-infrared spectroscopy (NIRS) is a rapid, continuous,
and non-invasive monitoring system of hemoglobin oxygen
saturation in muscle and the brain, and has been used to
assess the presence and extent of both circulatory and
metabolic disorders in intensive care patients and trauma
patients [8,9]. The monitoring system uses near-infrared light
(680 to 800 nm) to illuminate tissue, which is mainly
absorbed by  hemoglobin and myoglobin [10]. Due to the
selected wavelength range and the high corresponding
spectral absorbance by (de)oxyhemoglobin, the NIRS
measurements are confined to vessels with a diameter
<500 μm.
Using NIRS, oxyhemoglobin can be distinguished from de-
oxyhemoglobin because of their differing optical absorption
spectra. The ratio of oxyhemoglobin concentration to deoxy-
hemoglobin concentration is used to calculate a parameter
called tissue oxygen saturation (StO2), describing the
oxygenation of the microvasculature in a certain volume of
(muscular) tissue. In addition to steady-state StO2 values,
NIRS can be used in combination with a vascular occlusion
test (VOT), which consists of a baseline phase, an ischemia
phase, a reperfusion phase, and a reactive hyperemia
phase. Using this methodology in many studies of sepsis, it
has been demonstrated in a variety of ways that, following a
brief period of ischemia, there is an anomalous tissue
reperfusion profile due to disturbed microcirculatory
functioning [11,12].
The purpose of the present study was to test the hypothesis
that rh-aPC treatment corrects tissue perfusion and micro-
circulatory reperfusion in septic patients, evaluated with NIRS
in combination with a VOT, and to explore whether the NIRS
parameters are related to macrohemodynamic indices,
metabolic status, and Sequential Organ Failure Assessment
(SOFA) score.
Materials and methods
Patients
The study was designed as a prospective observational
investigation. For the experimental group (rh-aPC group), we
enrolled all patients admitted to the 12-bed polyvalent
intensive care unit of the University Hospital of Ospedali
Riuniti, Ancona, Italy with a diagnosis of severe sepsis or
septic shock – based on the criteria of the International
Sepsis Definitions Conference ACCP/SCCM [13] – that
could receive rh-aPC treatment (continued infusion of
24 μg/kg/hour for 96 hours). We included patients with two
or more sepsis-related organ failures (that is, cardiovascular,
pulmonary or renal dysfunction, thrombocytopenia, metabolic
acidosis with high lactates) or sepsis-correlated acute
respiratory distress syndrome. Patients with absolute or
relative contraindications to rh-aPC therapy were enrolled
into the control group. At the onset of severe sepsis or septic
shock, the Acute Physiology and Chronic Health Evaluation II
score was calculated.
All patients were sedated, intubated, and mechanically
ventilated. They were hemodynamically monitored by arterial
femoral catheter with the PiCCO system (Pulsion, Munich,
Germany). All patients received fluid challenge, and, if
necessary, continuous infusion of inotropic (dobutamine) and
vasopressor (norepinephrine) agents to maintain a normal
cardiac index and intrathoracic blood volume index and to
maintain the mean arterial pressure between 70 and
100 mmHg.
Near-infrared spectroscopy
StO2 was measured by a tissue spectrometer (InSpectra™
Model 325; Hutchinson Technology Inc., Hutchinson, MN,
USA). The spectrometer consists of light detection circuitry
and an optical cable that transmits light to tissues and
receives scattered light from tissues. The maximum depth of
the tissue volume sampled is estimated to be equal to the
distance between the sending and receiving fibers of the
probe (probe spacing). A probe spacing of 15 mm was used,
with the probe placed on an adhesive surface on the skin of
the volar surface of the forearm at the level of the brachio-
radial muscle. The VOT was applied using a sphygmo-
manometer cuff around the same arm that was inflated to
60 mmHg above the systolic arterial pressure to obtain an
arterial occlusion (stagnant ischemia) until StO2 decreased to
40%. StO2 was monitored continuously before (baseline) and
during (ischemia) pneumatic compression and after cuff
release (reperfusion).
Data were analyzed using InSpectra™ software to plot and
measure the StO2 curve characteristics; that is, baseline
StO2 (StO2 baseline), rate of decrease in StO2 during the VOT
(StO2 downslope), and rate of increase in StO2 during the
reperfusion phase (StO2 upslope). Data were collected before
(T0), during (24 hours (T1a), 48 hours (T1b), 72 hours (T1c),
and 96 hours (T1d)), and 6 hours (T2) after rh-aPC treatment
(that is, 102 hours from T0), and at the same times in the
controls. At all time points (except at 96 hours) the following
measurements were obtained: mean arterial pressure, dose
of norepinephrine, arterial blood lactate and base excess,
cardiac index and intrathoracic blood volume index, and
SOFA score.
Statistical analysis
Results are expressed as the mean ± standard deviation, and
as the median (first to third interquartile range) for catechol-
amines. Parametric statistics were applied for all parameters –
except for catecholamines, for which nonparametric statistics
were utilized. A two-way analysis of variance test was used to
assess differences between groups; a paired t  test was
applied to test differences between times within each group,
while an unpaired t  test with Welch correction when
indicated was applied to test differences at each time
between groups. The Friedman test was used to test
significant differences during time within each group, the
Wilcoxon test was used to test differences between eachtime point and T0, and the Mann–Whitney U test was used to
test for differences between groups. P <0.05 was
considered statistically significant.
Results
We studied 11 patients (four female and seven male) with
severe sepsis or septic shock who received rh-aPC therapy
(continued infusion of 24 μg/kg/hour for 96 hours) and a
control group of five patients (two female and three male)
who could not receive rh-aPC because of contraindications.
The patient characteristics are presented in Table 1. On
admission to the intensive care unit, the mean Acute
Physiology and Chronic Health Evaluation II score was
26.3 ± 6.6 for the rh-aPC group and 28.6 ± 5.3 for the
control group, with a risk of death of 41.0 ± 22.9% and
57.6 ± 25.7%, respectively. The mortality rate was 36.4% in
the rh-aPC group and 60% in the control group.
Four patients in the rh-aPC group (Table 1, Patients 2, 4, 9,
and 11) and one patient in the control group (Table 1, Patient
4) presented severe sepsis/septic shock on intensive care
unit admission, while the other patients developed sepsis
after admission to the intensive care unit.
From the two-way analysis of variance test, significant differ-
ences between groups were found for StO2 downslope (P <0.01),
StO2 upslope, the SOFA score (P <0.05) and the mean arterial
pressure (P <0.001).
The Friedman test showed that the norepinephrine and
dobutamine rates significantly decreased only in the rh-aPC
group (P <0.01), and not in the control group (Table 2).
The SOFA score, compared with T0, was significantly lower
at T1c and T1d (10.1 ± 2.3 vs. 8.8 ± 2.0 and 8.0 ± 2.3;
P <0.05) and at T2 (7.9 ± 2.2; P <0.01) (Figure 1). At T2 the
SOFA score was significantly reduced compared with the
control group (7.9 ± 2.2 vs. 12.2 ± 3.2; P <0.05). In the
control group, no differences were found with respect to
baseline values.
There were no significant differences in the macrohemo-
dynamic parameters (cardiac index and intrathoracic blood
volume index) at T0, during therapy, and at T2 (Table 2). The
mean arterial pressure was no different at T0 between
groups, while it was significantly increased during treatment
only in the rh-aPC group (T2 93.8 ± 12.8 vs. T0
81 ± 10.9 mmHg) (Figure 2).
With regard to metabolic acidosis in the rh-aPC group,
base excess was significantly corrected (P <0.01) after
24 hours from T0 and remained corrected until T2
(Figure 3a). In the control group, base excess was
significantly corrected at T1a, T1b, T1c, and T2 (P <0.05)
(Figure 3a). Blood lactate was significantly decreased in the
rh-aPC group at T1d and T2 (2.8 ± 1.3 vs. 1.9 ± 0.7 mmol/l;
P <0.05) (Figure 3b).
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Table 1
Patient characteristics
Patient Diagnosis at admission Contraindication
rh-aPC group
1 Postoperative triple aortocoronary bypass
2 Mediastinitis after odontogenic abscess
3 Postoperative liver trauma
4 Severe acute respiratory distress syndrome
5 Severe trauma
6 Severe trauma
7 Postoperative urgent aortocoronary bypass
8 Postoperative esophagectomy
9 Postoperative intestinal perforation
10 Necrotic-hemorrhagic pancreatitis
11 Pulmonary aspergillosis
Control group
1 Intracerebral hematoma Craniotomy
2 Postoperative cerebral aneurysm Craniotomy
3 Postoperative abdominal aortic aneurysm Risk of bleeding
4 Septic shock for cholecystitis Risk of intracranial bleeding
5 Pancreatitis Risk of bleeding
rh-aPC, recombinant activated protein C.StO2 baseline was significantly higher at T1a, T1c and T2
(Figure 4), while in the control group it was significantly
higher at T2. StO2 downslope decreased significantly at all the
time points (Figure 5a) only in the rh-aPC group, and it was
significantly steeper in the rh-aPC-treated patients than in the
control patients at T1b and T2 (–16.5 ± 11.8 vs.
–8.1 ± 2.4%/minute). StO2 upslope increased significantly in
the rh-aPC group at T1b, T1c, T1d and T2 (Figure 5b), and
was significantly higher than in the controls at T1c, T1d and
T2 (101.1 ± 62.1 vs. 54.5 ± 23.8%/minute).
Discussion
The present prospective observational study investigated the
effects of rh-aPC treatment on the SOFA score, macrohemo-
dynamic parameters, and metabolic acidosis in severe sepsis
and septic shock. Additionally, and more importantly in the
Critical Care    Vol 13 Suppl 5 Donati et al.
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Table 2
Cardiac index, ITBVI, norepinephrine dose, and dobutamine dose before, during, and after rh-aPC treatment
T0 T1a T1b T1c T1d T2
rh-aPC group
Cardiac index 4.6 ± 1.3 4.6 ± 1.3 3.8 ± 0.7 4.1 ± 1.7 4.0 ± 1.0 4.1 ± 0.7
ITBVI 883 ± 207 874 ± 189 884 ± 203 922 ± 223 876 ± 213 872 ± 176
Norepinephrine* 0.22 0.22 0.22 0.22  0.17 0.14 
(0.16 to 0.35) (0.15 to 0.38) (0.14 to 0.34) (0.11 to 0.24) (0.02 to 0.23) (0.01 to 0.21) 
Dobutamine* 3.4 (1 to 4.8) 2.8 (1 to 3.25) 2.1 (0 to 3.4) 2.1 (0 to 3.1) 2 (0 to 3.1) 2 (0 to 3.1)
Control group
Cardiac index 4.2 ± 0.6 4.1 ± 1.1 4.3 ± 0.7 4.2 ± 0.5 4.1 ± 0.8 4.1 ± 0.7
ITBVI 892 ± 249 894 ± 211 926 ± 208 897 ± 265 913 ± 280 891 ± 260
Norepinephrine 0.17 0.37 0.27 0.27  0.37 0.37 
(0.06 to 0.37) (0.11 to 0.5) (0.11 to 0.37) (0.11 to 0.37) (0.11 to 0 to 4) (0.11 to 0.4)
Dobutamine 4.2 (0 to 5.3) 0 (0 to 3.7) 0 (0 to 3.7) 2.3 (0 to 3.7) 2.3 (0 to 3.7) 2.3 (0 to 3.7)
Data are presented as the mean ± standard deviation or as the median (first to third interquartile range). Data were collected before (T0), during
(24 hours (T1a), 48 hours (T1b), 72 hours (T1c), and 96 hours (T1d)), and 6 hours (T2) after recombinant activated protein C (rh-aPC) treatment
(that is, 102 hours from T0). ITBVI, intrathoracic blood volume index. *P <0.01, Friedman test in the rh-aPC group.
Figure 1
Sequential Organ Failure Assessment score before, during, and after
recombinant activated protein C treatment. The Sequential Organ
Failure Assessment (SOFA) score in the recombinant activated protein
C (rh-aPC) group before, during, and after rh-aPC treatment, and in the
control group at the same times. Data were collected before (T0),
during (24 hours (T1a), 48 hours (T1b), 72 hours (T1c), and 96 hours
(T1d)), and 6 hours (T2) after rh-aPC treatment (that is, 102 hours
from T0). ANOVA, analysis of variance.
Figure 2
Mean arterial pressure before, during, and after recombinant activated
protein C treatment. Mean arterial pressure (MAP) in the recombinant
activated protein C (rh-aPC) group before, during, and after rh-aPC
treatment, and in the control group at the same times. Data were
collected before (T0), during (24 hours (T1a), 48 hours (T1b),
72 hours (T1c), and 96 hours (T1d)), and 6 hours (T2) after rh-aPC
treatment (that is, 102 hours from T0). ANOVA, analysis of variance.context of sepsis, the tissue oxygenation, metabolism, and
microvascular reperfusion dynamics were assessed using
NIRS in combination with a VOT to study any beneficial
effects of rh-aPC therapy at the microcirculatory level. It was
shown that rh-aPC treatment significantly lowered the SOFA
score, increased the mean arterial pressure, and reduced the
blood lactate concentration. Furthermore, rh-aPC had
positive effects on the VOT-derived StO2 parameters; both
StO2 downslope and StO2 upslope increased significantly,
indicating raised oxygen consumption/metabolism and indica-
ting improved microvascular reperfusion following ischemia.
Early goal-directed therapy focused on restoring macrohemo-
dynamics has been shown to be insufficient in preventing
cellular hypoxia and organ failure due to the heterogeneous
nature of sepsis-related microcirculatory dysfunction. It has
been shown that improvement in hemodynamic parameters
with vasoconstrictors, such as norepinephrine, could make
tissue perfusion worse [14],and several studies have demon-
strated the positive effects of vasodilators on microcirculatory
recruitment even in hemodynamically resuscitated septic
patients [15]. rh-aPC treatment has been shown to improve
end-organ function and to decrease mortality if started in the
early stages of sepsis [5-7] by restoring the coagulative
cascade, the inflammatory response, leukocyte adhesion and
migration, and endothelial function. In addition to the anti-
coagulant, profibrinolytic [16], and anti-inflammatory effects
and the antioxidant properties [17,18], rh-aPC acts at the
microcirculation level to enhance the proportion of perfused
capillaries and improve local autoregulation [1,19-21]. These
studies were mostly carried out in animals. De Backer and
co-workers [22] were the first to show the beneficial effects
of rh-aPC on microcirculatory perfusion by direct observation
of the sublingual microcirculation of septic patients using
OPS imaging. To our knowledge, however, the direct effects
of rh-aPC treatment on tissue oxygenation have not been
studied before.
Many studies have shown the relevance of StO2 in the
assessment of the metabolic and microcirculatory state in
septic patients. Doerschug and colleagues [23], De Blasi and
colleagues [10], Skarda and colleagues [24], and Pareznik
and colleagues [25] all showed that tissue oxygen
consumption was lower in septic patients than in nonseptic
patients or healthy volunteers and that septic patients have
slower tissue reoxygenation following ischemia. In addition,
Creteur and colleagues [12] demonstrated that persistent
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Figure 3
Base excess and blood lactate before, during, and after recombinant activated protein C treatment. (a) Arterial base excess (BE) and (b) blood
lactate in the recombinant activated protein C (rh-aPC) group before, during, and after rh-aPC treatment, and in the control group at the same
times. Data were collected before (T0), during (24 hours (T1a), 48 hours (T1b), 72 hours (T1c), and 96 hours (T1d)), and 6 hours (T2) after rh-aPC
treatment (that is, 102 hours from T0). ANOVA, analysis of variance; n.s., not significant.
Figure 4
Baseline tissue oxygen saturation before, during, and after recombinant
activated protein C treatment. Baseline tissue oxygen saturation (StO2
baseline) in the recombinant activated protein C (rh-aPC) group before,
during, and after rh-aPC treatment, and in the control group at the
same times. Data were collected before (T0), during (24 hours (T1a),
48 hours (T1b), 72 hours (T1c), and 96 hours (T1d)), and 6 hours (T2)
after rh-aPC treatment (that is, 102 hours from T0). ANOVA, analysis
of variance; n.s., not significant.alteration of StO2 resaturation correlated with worse outcome
and multiorgan failure.
The steady-state tissue oxygenation (StO2 baseline) did not
change as a result of rh-aPC treatment, which indicates that
the balance between tissue oxygen delivery and consumption
is unaltered by rh-aPC infusion. StO2 downslope, in contrast,
increased significantly after starting the rh-aPC therapy,
indicating increased cellular oxygen consumption. Additionally,
StO2 upslope increased significantly due to rh-aPC treatment,
which indicates the improved ability of the microcirculation to
be reperfused after a brief period of ischemia. Microvascular
function is therefore improved by rh-aPC treatment. This
finding is also supported by the reduced SOFA score and
lactate levels.
The present study has some limitations: firstly, the small
number of patients – in particular in the control group, where
patients affected by head trauma and intracranial hyper-
tension could have an altered systemic hemodynamic; and
secondly, because the NIRS technique itself has some limita-
tions. StO2 downslope has been asserted to indicate the muscle
oxygen consumption, but oxygen consumption cannot be
directly measured as the amount of hemoglobin in the
respective muscle blood volume is not known. The parameter
being measured is the oxygen consumption rate extrapolated
from the decrease in saturation of hemoglobin (StO2
decrease rate, %/minute), which is an index of the basic
metabolism of the thenar muscle. Moreover, whether the
concentration of hemoglobin affects the oxygen consumption
rate is not known. One argument regarding the reperfusion
rate is that NIRS does not measure blood flow and it must be
assumed that an increase in StO2 reflects endothelium-
dependent vasodilation. The extent to which comorbidites
such as atherosclerosis, age, gender or mental stress may
influence this parameter is not known. Regardless of these
limitations, the ability to provide a non-invasive, reproducible
estimate of the oxygen consumption rate of skeletal muscle at
the bedside renders this technique potentially useful in
clinical practice.
Conclusion
Treatment of septic patients with continuous infusion of rh-
aPC may improve tissue oxygenation, cellular metabolism,
and microvascular reactivity, and may significantly reduce the
SOFA score and lactate levels. NIRS in combination with a
VOT was able to detect microcirculatory and metabolic
changes associated with sepsis and rh-aPC treatment.
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